Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)

Brief description of study

The purpose of this study is to evaluate the CardiAMP cell therapy system as a treatment for patients with heart failure as a result of previous heart attack. Patients with heart failure after a previous heart attack may experience shortness of breath and fatigue while doing ordinary activities, and may notice fluid buildup (edema) in the legs. The bone marrow, which is located at the internal part of some bones such as the hipbones, produces special blood cells that may help body tissues after an injury, including the heart after a heart attack. This study is being done to measure the effects of special bone marrow blood cell injection into the heart on heart function and symptoms. The blood cells used in these injections are taken from you. The CardiAMP cell therapy system is investigational. This means it has not been approved by the US Food and Drug Administration (FDA).


Clinical Study Identifier: s19-00052
ClinicalTrials.gov Identifier: NCT02438306
Principal Investigator: Stuart D. Katz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.